ANIX
Anixa Biosciences Inc (ANIX
NASDAQ · Healthcare · Biotechnology · US
$3.16
+3.42%Oct 26, 2026, 12:30 UTC
Anixa Biosciences announced completion of dosing in the fifth cohort of its Phase 1 FSHR-targeted CAR-T trial for recurrent ovarian cancer, with patients receiving 1×10⁷ CAR-positive cells/kg after lymphodepletion.
Source:Sep 29, 2026, 23:59 UTC
Anixa Biosciences is developing a breast cancer vaccine, currently about one-third of the way through human testing, designed to prevent recurrence and potentially the disease itself.
Source:Sep 21, 2026, 12:45 UTC
Anixa Biosciences received an Australian patent for its breast cancer vaccine.
Source:Jun 29, 2026, 12:45 UTC
Anixa Biosciences was granted a Korean patent for its breast cancer vaccine by the Korean Ministry of Intellectual Property, extending protection through 2040.
Source:Jun 1, 2026, 13:00 UTC
Anixa Biosciences received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering its ovarian cancer vaccine technology.
Source: